Shanghai Pioneer Holding Ltd (1345) AI Stock Analysis

• Market Cap: HK$2.67B
• Dividend Yield: 4.68%
• Average Volume (3M): 90.10K
• Price to Earnings (P/E): 15.7
• Beta (1Y): 0.06
• Revenue Growth: -4.04%
• EPS Growth: 2.92%
• Country: HK
• Employees: 335
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.05
• Shares Outstanding: 1,257,447,000
• 10 Day Avg. Volume: 58,900
• 30 Day Avg. Volume: 90,100
• PEG Ratio: -2.15
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.50
• Price Target Upside: 12.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: HK$2.50 ▲(12.61%Upside)

Shanghai Pioneer Holding Ltd is well-positioned with strong financial health and a reasonable valuation. However, the neutral technical indicators suggest a cautious market sentiment. The stock's appeal is bolstered by its solid dividend yield, providing good potential for income-focused investors.

Shanghai Pioneer Holding Ltd Business Overview & Revenue Model

Company Description

China Pioneer Pharma Holdings Limited, an investment holding company, markets, promotes, and sells pharmaceutical products and medical devices primarily in the People's Republic of China. It has a portfolio of pharmaceutical products, such as ophthalmology, pain management, cardiovascular, immunology, gynecology, gastroenterology, and other therapeutic areas, as well as medical devices, including ophthalmology, orthopedics, odontology, and wound care products. The company sells its products to hospitals and medical institutions, and pharmacies. It also sells ancillary tools and leases accessories; and sells dental devices. In addition, the company engages in the sale of imported in-licensed prescription products. China Pioneer Pharma Holdings Limited was founded in 1996 and is headquartered in Shanghai, the People's Republic of China. China Pioneer Pharma Holdings Limited is a subsidiary of Pioneer Pharma (BVI) Co., Ltd.

How the Company Makes Money

Shanghai Pioneer Holding Ltd makes money through two primary revenue streams: sales of developed properties and property management services. The company generates significant revenue from selling residential and commercial units within its developed projects. Additionally, it earns recurring income by offering property management services, which include maintenance, security, and facility management for its developed properties. The company's earnings are influenced by the real estate market conditions in China and its ability to successfully complete and sell its development projects.

Shanghai Pioneer Holding Ltd Financial Statement Overview

Summary

Shanghai Pioneer Holding Ltd demonstrates strong financial health with a robust balance sheet and efficient cost management. However, variability in profitability and cash flow slightly dampens the overall financial performance score.

Income Statement

Shanghai Pioneer Holding Ltd shows a consistent revenue base with moderate growth. The gross profit margin is healthy, reflecting efficient cost management. However, the net profit margin has fluctuated, indicating some instability in profitability. The EBIT and EBITDA margins are stable, suggesting solid operational efficiency.

Balance Sheet

The balance sheet is robust, with a low debt-to-equity ratio signifying strong financial health and low leverage. The return on equity indicates efficient use of shareholders’ funds, although there is room for improvement. The equity ratio demonstrates a stable capital structure, providing a solid foundation for future growth.

Cash Flow

The company has shown strong free cash flow growth, rebounding from previous negative figures, which supports operational investments and reduces financial risk. The operating cash flow to net income ratio is positive, indicating good cash conversion. However, fluctuations in free cash flow to net income ratio suggest potential variability in cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.53B	1.57B	1.56B	1.43B	1.33B
Gross Profit	683.21M	668.24M	780.47M	772.03M	607.97M
EBITDA	215.27M	201.88M	245.38M	199.96M	104.79M
Net Income	151.62M	145.72M	235.30M	142.63M	52.45M
Balance Sheet
Total Assets	1.46B	1.53B	1.57B	1.33B	1.43B
Cash, Cash Equivalents and Short-Term Investments	103.57M	124.43M	289.01M	402.08M	254.61M
Total Debt	75.22M	74.02M	37.59M	14.05M	15.10M
Total Liabilities	342.52M	513.14M	549.18M	417.49M	516.73M
Stockholders Equity	1.11B	1.01B	1.01B	907.97M	909.43M
Cash Flow
Free Cash Flow	208.01M	-163.24M	19.02M	225.43M	39.37M
Operating Cash Flow	214.83M	-118.69M	93.30M	242.06M	74.24M
Investing Cash Flow	-99.76M	69.51M	-12.99M	8.39M	23.93M
Financing Cash Flow	-125.92M	-50.56M	-91.03M	-140.28M	-253.04M

Shanghai Pioneer Holding Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1345, the sentiment is Positive. The current price of 2.22 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.16, and above the 200-day MA of 2.16, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 56.53 is Neutral, neither overbought nor oversold. The STOCH value of 75.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1345.

Shanghai Pioneer Holding Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2219	75 Outperform	HK$2.10B	9.68	8.35%	8.42%	0.61%	-15.89%
2633	74 Outperform	HK$3.17B	11.02	12.47%	3.89%	7.43%	21.88%
2348	73 Outperform	HK$2.07B	3.39	18.33%	5.37%	-9.95%	67.56%
1110	71 Outperform	HK$345.70M	7.29	6.61%	5.47%	-3.59%	4.81%
1345	70 Outperform	HK$2.67B	15.72	14.36%	4.68%	-4.04%	2.92%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%
3390	45 Neutral	HK$303.96M	80.95	0.64%	20.00%	-26.91%	-98.72%

Shanghai Pioneer Holding Ltd Corporate Events

Shanghai Pioneer Holding Ltd Updates Nomination Committee

Shanghai Pioneer Holding Ltd has announced changes in the composition of its nomination committee, appointing Ms. Hu Mingfei and Mr. Zhang Changhai as new members. This move aligns with the upcoming amendments to the Listing Rules and Corporate Governance Code, effective July 1, 2025, and aims to enhance board effectiveness, diversity, and overall corporate governance.

Shanghai Pioneer Holding Ltd Announces Board Restructuring

Shanghai Pioneer Holding Ltd has announced changes to its board of directors, effective from June 30, 2025. The update includes the appointment of Mr. Li Xinzhou as Chairman, with Mr. Yang Yuewen and Mr. Zhang Quan as executive directors, Ms. Hu Mingfei as a non-executive director, and Mr. Zhang Hong, Mr. Lai Chanshu, and Mr. Zhang Changhai as independent non-executive directors. These changes are expected to influence the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relations.

Shanghai Pioneer Holding Ltd Updates Nomination Committee Terms

Shanghai Pioneer Holding Ltd has announced the amendment of the terms of reference for its Nomination Committee, effective from June 30, 2025. The committee is tasked with identifying and recommending candidates for the board of directors, ensuring diversity and independence in its composition, and meeting at least annually to fulfill its responsibilities. This move is expected to enhance the governance and operational efficiency of the company, aligning with the listing rules of the Hong Kong Stock Exchange and potentially strengthening its market position.

Shanghai Pioneer Holding Ltd AGM: All Resolutions Passed, Dividend Declared

Shanghai Pioneer Holding Ltd successfully conducted its Annual General Meeting on May 30, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of directors, the authorization for the board to fix directors’ remuneration, the reappointment of BDO Limited as auditor, and the approval of a general mandate for share allotment and repurchase. The company also declared a final dividend, indicating a stable financial position and continued shareholder value focus.